stockrow
Friday 6 November 2026
Export SOPH’s income statement to Excel — free account
SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024.
- Revenue
- +24.7%
- EPS
- +21.0%
- Free cash flow
- −1.87%
- Total debt
- +1.19%
Quarter to September 2026, against a year earlier
7.08
0.46
+6.95%
Follow SOPH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 25 | 28 | 40 | 48 | 62 | 65 | 77 | 91 | +20.4% | 95 | 119 | 154 | +25.9% | |
| Gross margin, % | — | — | — | 70.30 | 62.29 | 62.35 | 65.71 | 68.80 | 67.42 | 67.40 | 66.43 | (2.9) pt | ||||||
| EBT | — | — | — | (34) | (41) | (74) | (88) | (78) | (61) | (77) | (81) | +14.9% | ||||||
| EBT margin, % | — | — | — | (132.60) | (145.16) | (181.72) | (184.16) | (125.85) | (94.01) | (100.28) | (88.91) | +32.3 pt | ||||||
| Net income | — | 0 | — | (34) | (41) | (74) | (88) | (78) | (61) | (77) | (81) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.67 | 0.67 | 0.73 | 0.74 | 0.96 | 0.99 | 1.14 | 1.06 | +9.3% | |||||
| Earnings | — | — | — | (0.90) | (0.93) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) | (1.09) | +4.6% | ||||||
| Cash flow | — | — | — | (0.84) | (0.75) | (1.05) | (1.09) | (0.75) | (0.67) | (0.53) | (0.47) | (7.3%) | ||||||
| Capex | — | — | — | (0.08) | (0.02) | (0.05) | (0.07) | (0.03) | (0.01) | (0.01) | (0.01) | (29.2%) | ||||||
| Free cash flow | — | — | — | (0.92) | (0.77) | (1.10) | (1.16) | (0.78) | (0.68) | (0.54) | (0.49) | (8.4%) | ||||||
| Book value | — | — | — | 0.59 | 2.37 | 4.98 | 3.12 | 2.34 | 1.46 | 0.70 | 0.80 | +2.9% | ||||||
| Shares, m | — | — | — | 38 | 42 | 55 | 64 | 65 | 66 | 68 | 75 | +10.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 24.00 | 24.00 | 19.28 | 3.03 | 5.01 | 3.11 | 4.08 | 6.24 | 11.8 | ||||||
| P/B | — | — | — | 11.53 | 11.53 | 2.83 | 0.72 | 2.07 | 2.10 | 6.69 | 8.30 | 5.4 | ||||||
| EV/Sales | — | — | — | 22.24 | 22.24 | 13.04 | (0.39) | 3.30 | 2.11 | 3.81 | 5.76 | 9.5 | ||||||
| EV/FCF | — | — | — | (15.91) | (15.91) | (8.68) | 0.25 | (4.09) | (3.06) | (8.04) | (12.59) | (7.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (32) | (32) | (58) | (70) | (49) | (45) | (36) | (40) | +2.1% | |||||
| Capex | — | — | — | (3) | (1) | (3) | (5) | (2) | 0 | (1) | (1) | (22.0%) | ||||||
| Free cash flow | — | — | — | (35) | (32) | (61) | (75) | (50) | (45) | (37) | (42) | +0.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 15 | 88 | 254 | 169 | 112 | 73 | 49 | 71 | +22.3% | |||||
| Net debt | — | — | — | (15) | (94) | (254) | (165) | (123) | (67) | (23) | (46) | +7.5% | ||||||
| Shareholders’ equity | — | — | — | 22 | 101 | 275 | 200 | 151 | 96 | 47 | 68 | +13.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (130.83) | (42.81) | (32.58) | (31.01) | (35.10) | (34.58) | (49.63) | (46.60) | +81.2 pt | |||||
| ROIC | — | — | — | (263.58) | (359.77) | (209.50) | (154.31) | (165.89) | (141.03) | (180.23) | (200.89) | +83.4 pt | ||||||
| ROE | — | — | — | (55.05) | (64.09) | (39.20) | (36.78) | (44.93) | (50.41) | (110.00) | (125.67) | (55.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 462 | 518 | 466 | 449 | 423 | 415 | — | (2.1%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.06 | 0.08 | 0.10 | 0.14 | 0.15 | 0.19 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
SOPHiA GENETICS SA vs peers in Health Information Services (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings, Inc. | $1.2B | 65.7× | 46.0× | −1.31% (below 0%: shrinking) | −25.00% (below 0%: shrinking) | +112.45% (above 0%: growing) | 89.52% | 11.79% | Compare |
| OMDA Omada Health, Inc. | $1.2B | 267× | 156× | +43.12% (above 0%: growing) | n/m | +45.71% (above 0%: growing) | 72.62% | 4.04% | Compare |
| HSTM HealthStream, Inc. | $905.6M | 42.0× | 45.4× | +8.94% (above 0%: growing) | −8.90% (below 0%: shrinking) | −4.80% (below 0%: shrinking) | 63.98% | 7.91% | Compare |
| PHR Phreesia, Inc. | $788.9M | 74.4× | 40.2× | +10.41% (above 0%: growing) | +200.00% (above 0%: growing) | +43.51% (above 0%: growing) | 66.64% | 5.88% | Compare |
| NRC National Research Corporation | $563.6M | 87.6× | 61.1× | +10.95% (above 0%: growing) | +22.22% (above 0%: growing) | −31.38% (below 0%: shrinking) | 59.95% | 23.20% | Compare |
| SOPH SOPHiA GENETICS SA | $563.6M | — (loss-making) | — (loss-making) | +24.69% (above 0%: growing) | n/m | −1.87% (below 0%: shrinking) | 65.66% | (73.45%) | |
| EVH Evolent Health, Inc | $513.3M | — (loss-making) | — (loss-making) | +51.27% (above 0%: growing) | n/m | +179.84% (above 0%: growing) | 12.19% | (0.85%) | Compare |
| CARL Carlsmed, Inc. | $418.3M | — (loss-making) | — (loss-making) | +56.75% (above 0%: growing) | n/m | −6.84% (below 0%: shrinking) | 76.78% | (58.27%) | Compare |
| CTEV Claritev Corporation | $342.7M | — (loss-making) | — (loss-making) | +6.59% (above 0%: growing) | n/m | +49.10% (above 0%: growing) | 73.72% | 9.09% | Compare |
| Median of peers | $676.3M | 74.4× | 46.0× | +10.68% | +6.66% | +44.61% | 69.63% | 6.90% |